News and Analysis

Non-alcoholic steatohepatitis (NASH) affects 5% of US adults, but currently has no FDA-approved therapy. However, advancements in NASH treatments are being made. Madrigal Pharmaceuticals showed promise in a phase 3 trial using resmetirom, with a 30% resolution of liver biopsy findings observed. Akero Therapeutics’ EFX also showed a 65% reduction in liver fat when combined with GLP-1 drugs. A UC San Diego School of Medicine study showed Pegozafermin improved liver fibrosis and inflammation in NASH patients. Meanwhile, Icahn School of Medicine researchers identified 68 new drug targets against NAFLD.